RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-17.9%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.58B
AUM Growth
+$4.58B
(-19%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
5.84%
Top 10 Holdings %
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$153M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$68.6M |
| 3 |
AN2 Therapeutics
ANTX
|
$55.3M |
| 4 |
Natera
NTRA
|
$53.3M |
| 5 |
Vera Therapeutics
VERA
|
$46.2M |
Top Sells
| 1 |
Novavax
NVAX
|
$103M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
$61.3M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$54.2M |
| 4 |
C4 Therapeutics
CCCC
|
$44.4M |
| 5 |
TG Therapeutics
TGTX
|
$42M |
Sector Composition
| 1 | Healthcare | 97.97% |
| 2 | Financials | 0.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $888M | 19.38% | 7,567,900 | – | – |
|
|
2
Biogen
BIIB
$19.4B
| $153M | 3.34% | +727,024 | New | +$153M |
|
|
JBIO
3
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $151M | 3.31% | 8,263,982 | – | – |
|
4
Cytek Biosciences
CTKB
$527M
| $144M | 3.15% | 13,381,054 +3,774,026 | +39% | +$40.7M |
|
5
iTeos Therapeutics
ITOS
| $142M | 3.1% | 4,417,259 | – | – |
|
6
Travere Therapeutics
TVTX
$1.56B
| $127M | 2.77% | 4,922,941 -691,487 | -12% | -$17.8M |
|
7
Janux Therapeutics
JANX
$1.37B
| $124M | 2.71% | 8,670,644 | – | – |
|
8
Vaxcyte
PCVX
$4B
| $111M | 2.41% | 4,581,203 +340,739 | +8% | +$8.23M |
|
|
CLYM
9
Climb Bio, Inc. Common Stock
CLYM
$151M
| $110M | 2.41% | 13,150,849 | – | – |
|
|
IMGN
10
DELISTED
Immunogen Inc
IMGN
| $103M | 2.26% | 21,741,458 +1,500,000 | +7% | +$7.14M |
|
|
DICE
11
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $99.6M | 2.17% | 5,208,911 | – | – |
|
12
GH Research
GHRS
$837M
| $88.3M | 1.93% | 4,827,330 +1,983,573 | +70% | +$36.3M |
|
|
FMTX
13
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $83.8M | 1.83% | 9,011,651 | – | – |
|
14
Tyra Biosciences
TYRA
$675M
| $77.4M | 1.69% | 7,236,454 | – | – |
|
|
PNT
15
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $71.8M | 1.57% | 9,003,018 | – | – |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $70.7M | 1.54% | 2,075,000 +270,205 | +15% | +$9.2M |
|
|
BLU
17
DELISTED
BELLUS Health Inc.
BLU
| $70.4M | 1.54% | 10,230,274 | – | – |
|
|
18
Enanta Pharmaceuticals
ENTA
$180M
| $68.6M | 1.5% | +964,212 | New | +$68.6M |
|
19
Vor Biopharma
VOR
$250M
| $67.2M | 1.47% | 11,120,973 | – | – |
|
20
Nkarta
NKTX
$151M
| $63.8M | 1.39% | 5,605,129 | – | – |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $60.4M | 1.32% | 734,343 +353,297 | +93% | +$29M |
|
22
Day One Biopharmaceuticals
DAWN
$769M
| $60.1M | 1.31% | 6,060,090 +1,094,502 | +22% | +$10.9M |
|
23
Rhythm Pharmaceuticals
RYTM
$6.85B
| $56.1M | 1.22% | 4,871,067 | – | – |
|
|
24
AN2 Therapeutics
ANTX
$30.1M
| $55.3M | 1.21% | +3,666,663 | New | +$55.3M |
|
25
Relmada Therapeutics
RLMD
$37.2M
| $54M | 1.18% | 2,000,000 | – | – |
|